ORCID as entered in ROS

Select Publications
2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218
,2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', The Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6
,2024, 'Neutrophils under the microscope: neutrophil dynamics in infection, inflammation, and cancer revealed using intravital imaging', Frontiers in Immunology, 15, http://dx.doi.org/10.3389/fimmu.2024.1458035
,2023, 'Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy', Cancer Research, 83, pp. 1315 - 1328, http://dx.doi.org/10.1158/0008-5472.CAN-21-4025
,2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398
,2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677
,2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104
,2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552
,2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002
,2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557
,2020, 'Imaging the neutrophil: Intravital microscopy provides a dynamic view of neutrophil functions in host immunity', Cellular Immunology, 350, http://dx.doi.org/10.1016/j.cellimm.2019.01.003
,2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120
,2020, 'Microbial activation converts neutrophils into anti-tumor effectors', , http://dx.doi.org/10.1101/2020.08.21.259051
,2019, 'The ins and outs of chemokine-mediated immune cell trafficking in skin cancer', Frontiers in Immunology, 10, http://dx.doi.org/10.3389/fimmu.2019.00386
,2017, 'P3.02c-055 Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies', Journal of Thoracic Oncology, 12, pp. S1308 - S1308, http://dx.doi.org/10.1016/j.jtho.2016.11.1850
,2013, 'Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor êb and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells', Diabetologia, 56, pp. 520 - 532, http://dx.doi.org/10.1007/s00125-012-2784-x
,2009, 'Incidence of sterile cerebrospinal fluid pleocytosis in infants with urinary tract infection', Journal of Paediatrics and Child Health, 45, pp. 364 - 367, http://dx.doi.org/10.1111/j.1440-1754.2009.01502.x
,2008, 'GENERATING ISLET ALLOGRAFT TOLERANCE BY BLOCKING NF-KB ACTIVATION AND PREVENTING APOPTOSIS.', Transplantation, 86, pp. 18 - 18, http://dx.doi.org/10.1097/01.tp.0000332732.20615.8f
,2006, 'Nuclear Factor-KB regulates beta-cell death - A critical role for A20 in beta-cell protection', Diabetes, 55, pp. 2491 - 2501
,2003, 'Modification of in viro and in vitro T- and B-Cell-Mediated Immune Responses by the Pseudomonas aeruginosa Quorum-Sensing Molecule N-(3-Oxododecanoyl)-L-Homoserine Lactone', Infection and Immunity, 71, pp. 4421 - 4431
,2003, 'Modification of in vivo and in vitro T- and B-cell-mediated immune responses by the Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-L-homoserine lactone', INFECTION AND IMMUNITY, 71, pp. 4421 - 4431, http://dx.doi.org/10.1128/IAI.71.8.4421-4431.2003
,